Research programme: musculoskeletal disorder therapeutics - Five Prime Therapeutics/GlaxoSmithKline

Drug Profile

Research programme: musculoskeletal disorder therapeutics - Five Prime Therapeutics/GlaxoSmithKline

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Five Prime Therapeutics; GlaxoSmithKline
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Musculoskeletal disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Musculoskeletal-disorders in USA
  • 15 Sep 2014 GlaxoSmithKline exercises its option to obtain an exclusive worldwide license to products for the treatment of undisclosed muscle disease target
  • 31 Oct 2013 GlaxoSmithKline exercises its option to several protein therapeutic targets discovered by Five Prime Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top